Seoul National University

Nano Intelligent Biomedical Engineering Corporation Co. Ltd.

Nibec Co., Ltd.

Snur & Db Foundation

University of Michigan

Chungbuk National University Industry-academic Cooperation Foundation

Yoon Jeong Park

Chong-Pyoung Chung

Jue-Yeon Lee

Jin Sook Suh

Dong Woo Lee

Yeonsu Kim

Yoon Shin Park

Hyun Kil Nam

Seung Jin Lee

Victor C Yang

Seung Hyun Han

Ok-Jin Park

Gene Lee

Sang Hoon Rhee

Junfeng Liang

In Ho Jo

Yoon Jung Choi

Ki Bum Ahn

Kee-Yeon Kum

Joocheol Park

Ju Yeon Chae

The present invention relates to a GRP78-derived peptide for screening highly efficient stem cells and the use thereof, and more particularly, to screening highly efficient stem cells using, as a marker, a GRP78-derived peptide capable of binding to the binding domain of GRP78 protein on the cell surface. According to the present invention, the GRP78-derived peptide comprising only a specific amino acid sequence capable of recognizing highly efficient stem cells, among the amino acid sequence of GRP78, makes it possible to screen only non-senescent young stem cells. In addition, when stem cells are treated with the GRP78-derived peptide or the GRP78-derived peptide is introduced into stem cells, the efficiency of the stem cells can be increased. Thus, the GRP78-derived peptide is useful for the production of stem cell therapy products having excellent efficacy.

GRP78-derived peptide for identifying high-efficiency stem cells

The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. Moreover, the disease treatment effect can be enhanced by further fusing a peptide having intracellular permeability and an inflammation inhibitory function to the peptide.

Peptide capable of binding to biomarker for inflammatory and metabolic diseases, and use thereof

Disclosed are a bifunctional peptide having the capability to reduce inflammation and the capability to facilitate differentiation of stem cells into chondrocytes and the use thereof. Advantageously, the bifunctional peptide is useful for the prevention or treatment of arthritis accompanied by inflammation and damage of cartilage tissue due to excellent effects of reducing inflammation and facilitating differentiation of stem cells into chondrocytes, can be easily applied to various surgical regenerative treatments including orthopedic treatments, and can shorten the treatment period.

Bifunctional peptide having capability to reduce inflammation and capability to facilitate differentiation of stem cells into chondrocytes and use thereof

The present invention relates to a pharmaceutical composition for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide bound to parathyroid hormone (PTH) or a fragment thereof. More particularly, the present invention relates to a pharmaceutical composition and biomaterial for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide represented by an amino acid sequence of SEQ ID NO. 3 bound to parathyroid hormone (PTH) or a fragment thereof represented by an amino acid sequence of SEQ ID NO. 4 or 5. The fusion peptide can improve effects of PTH by selectively binding to bone tissue and can reduce administration frequency by increasing the half-life. The fusion peptide can be used as a subcutaneous or intravenous injection-type pharmaceutical composition for treating osteoporosis and fracture, and can be used in combination with a medical device for tissue recovery to increase formation of bone tissue. In addition, when the fusion peptide is bound to the surface of dental and orthopedic medical devices, transplantation stability of the medical device can be improved through improved osseointegration between the medical device and new bone.

Pharmaceutical composition and biomaterial comprising fusion peptide in which bone tissue-selective peptide bound to parathyroid hormone (PTH) or fragment thereof

A peptide derived from the copine 7 protein and having both cell permeability and bone tissue regeneration ability, and a use of the peptide, are described. The peptide has excellent bone tissue regeneration ability and is therefore useful for treating a disease requiring bone regeneration, such as osteoporosis. Particularly, by also having cell permeability, the peptide does not require the attachment of a separate peptide or addition of another preparation for the cell permeation thereof and thus can be conveniently applied in orthopedics and the like requiring various surgical regeneration treatments.

Dual functional novel peptide having cell permeability and bone tissue regeneration ability, and use thereof

The present invention relates to: a composition for inhibiting biofilms, containing, as an active ingredient, a peptide derived from human &#x3b2;-defensin-3; and a method for inhibiting biofilms by using the composition. The peptide according to the present invention inhibits bacterial biofilms even when used alone and exhibits a remarkably increased biofilm inhibitory effect when used in combination with a conventional dental therapeutic agent, and has an effect of preventing a tooth discoloration side effect caused by a conventional dental therapeutic agent.

Peptide for inhibiting biofilms

Disclosed are a bifunctional peptide having the capability to permeate cells and the capability to regenerate muscles and the use thereof. Advantageously, the bifunctional peptide has a function of regenerating muscle cells and thus is useful for the prevention or treatment of diseases affecting muscle regeneration, and additionally has the capability to permeate cells and thus eliminates the necessity to adhere an additional peptide or add other agent or drug for cell permeation of the peptide, thereby finally exerting an efficient muscle generation effect. Thus, the bifunctional peptide can be easily applied to various surgical regenerative treatments and can shorten the treatment period.

Bifunctional peptide having capability to permeate cells and capability to regenerate muscles and use thereof

The present invention relates to a peptide having the ability to bind specifically to the surface of titanium. The titanium-binding peptide according to the present invention is fixed securely to the titanium surface so that the activity of a physiologically active substance linked to the peptide can be stably maintained over a long period of time. Thus, the peptide can be effectively used for surgical regeneration therapy.

Peptide having titanium-binding ability

Provided are a tissue structure mimetic used for regenerating a tissue and a method for manufacturing the same, and more particularly, a 3-dimensional tissue structure mimetic which consists of a complex of extracellular matrix protein and bone mineral, wherein the complex is specifically bound to a regeneration-functional peptide to thereby be capable of implementing environment of a tissue requiring restoration, and a method for manufacturing the same. In the tissue structure mimetic according to the present invention, bone mineral components are finely dispersed in the extracellular matrix protein to have excellent mechanical strength of the tissue structure mimetic and conductivity which provides a migration path of cells involved in tissue regeneration. Further, environment of the tissue may be implemented by the peptide contained in the tissue structure mimetic to finally remarkably increase tissue regeneration capacity.

Mimetic tissue structure containing extracellular matrix protein-bone mineral complex and method for manufacturing same

The disclosure relates to a fat accumulation inhibitory peptide which essentially comprises an amino acid sequence represented by SEQ ID NO: 1, a pharmaceutical composition for preventing or treating obesity, which contains the peptide, and a health functional food for preventing or alleviating obesity, which contains the peptide. The fat accumulation inhibitory peptide according to the present invention has the function of inhibiting the differentiation of mesenchymal stem cells into adipocytes to thereby inhibit the accumulation of adipose tissue. Thus, the peptide according to the present invention is highly useful for the prevention or treatment of obesity.

Fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same

Provided is a method of preparing induced pluripotent stem cells using a synthetic peptide, and more particularly, to a method of preparing induced pluripotent stem cells using a peptide capable of inhibiting the activity of NF-&#x3ba;B and promoting mesenchymal-epithelial transition (MET). Since undifferentiated multipotent stem cells may be efficiently prepared under xenopathogen-free or feeder cell-free conditions without requiring co-culture with animal serum or xenogeneic cells, the method for preparing the induced pluripotent stem cells using the synthetic peptide according to the present disclosure is very useful for developing stem cell therapeutic agents that are clinically applicable.

Method for preparing induced pluripotent stem cells using synthetic peptide

The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-&#x3ba;B which is overexpressed specifically in cancer stem cells present in tumors.

Anticancer peptide for inhibiting proliferation of cancer stem cells and use thereof

A method of treating breast cancer is described, in which a peptide having cancer selective translocation function-doxoribicin conjugate is administered. The conjugate includes doxorubicin chemically linked to the N-terminus or C-terminus of a VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO:, wherein the VPTD peptide and doxorubicin are linked to each other by a disulfide bond, and wherein the VPTD peptide binds specifically to vascular endothelial growth factor (VEGF) in tumor cells or tumor tissues.

Peptide having cancer selective translocation function and use thereof

The present invention relates to a peptide that binds specifically to the surface of zirconia, and more particularly, to a peptide conjugate obtained by linking a functional drug to the peptide so as to enable the drug to be securely fixed to the surface of zirconia to thereby maintain the activity of the drug over a long period of time. The zirconia-binding peptide according to the present invention can be securely fixed to the surface of zirconia so that the activity of a physiologically active substance introduced into the peptide can be maintained on the zirconia surface over a long period of time. Thus, the zirconia-binding peptide is useful for surgical regenerative treatment.

Peptide having zirconia-binding capacity

A method of preparing a reprogramming induced pluripotent stem cell from a human-derived somatic cell using a fusion protein in which a reprogramming inducing factor and cell permeable peptide (CPP) are fused, and a fusion protein in which a reprogramming inducing factor and a cell permeable peptide are fused are disclosed. According to the present invention, the induced pluripotent stem cell having high efficiency and high stability can be prepared by maximizing the effect of the reprogramming inducing transcription factor beyond the existing viral peptide transporter, in inducing the reprogramming of the somatic cell.

Growing community of inventors

Seoul, South Korea

Yoon Jeong Park